TECDAX/ DE0007203275
TDXP2024-03-28 5:50:00 PM | Chg. -2.98 | Open | High | Low | Previous Close |
---|---|---|---|---|---|
3,454.38XXP | -0.09% | 3,457.48 | 3,462.49 | 3,449.47 | 3,457.36 |
|
GlobeNewswire
01-23
Bluebeam Harnesses the Power of AI and Customer Passion to Drive Innovation in the Built World
GlobeNewswire
2023-12-11
Glycotope and Evotec enter licensing agreement to combine Glycotope antibodies and Evotec’s immune c...
GlobeNewswire
2023-11-07
Dewpoint Therapeutics Enters Strategic Partnership with Evotec to Accelerate Oncology Pipeline
GlobeNewswire
2018-06-12
Software AG acquires Technology Scale-up TrendMiner for analysis and visualization of time series da...
GlobeNewswire
2016-12-13
MorphoSys Starts Phase 2 Trial of MOR208 in Combination with Idelalisib in Patients with Relapsed or...
GlobeNewswire
2016-12-06
MorphoSys Presents Updated Clinical Data for Blood Cancer Candidate MOR208 in NHL and CLL at ASH 201...
GlobeNewswire
2016-12-06
MorphoSys Presents Updated Clinical Results for Anti-CD38 Antibody MOR202 at ASH 2016
GlobeNewswire
2016-11-28
MorphoSys Announces That Its Licensee Janssen Has Submitted a Marketing Authorisation Application Fo...
GlobeNewswire
2016-11-17
MorphoSys Announces That Its Licensee Janssen Has Submitted Biologics License Application For Guselk...
GlobeNewswire
2016-11-15
MorphoSys Announces That Its Licensee Janssen Has Presented Positive Clinical Data of Guselkumab in ...
GlobeNewswire
2016-11-08
Anke Linnartz joins MorphoSys as Head of Corporate Communications and Investor Relations
GlobeNewswire
2016-11-03
MorphoSys Announces Presentations of Clinical Data at Upcoming American Society of Hematology (ASH) ...
GlobeNewswire
2016-11-02
MorphoSys and LEO Pharma Enter into Strategic Alliance to Develop Therapeutic Antibodies in Dermatol...
GlobeNewswire
2016-10-20
MorphoSys Receives Clinical Milestone for Start of Phase 1 Trial with Novel Cancer Antibody
GlobeNewswire
2016-10-17
MorphoSys Presents Updated Clinical Results for MOR202 at Medical Conference